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ABSTRACT: New coumarin-tethered benzimidazolium (BzICouRHCl) and imidazolium
(ICouRHCl) salts have been prepared as precursors for coumarin−NHC rhodium(I) complexes
RhCl(NHC)(cod). Trigonal bypiramidal pentacoordinated bis-coumarin−NHC rhodium(I)
species, RhCl(NHC)2, can be obtained by heating rhodium-cod derivatives in the presence of
coumarin−azolium salts and a base. These unusual species are stabilized by coordination of the
unsaturated bond of both coumarin moieties by the same enantioface. The allyl substituent on
doubly functionalized NHC competes for coordination with coumarin wingtips. DFT calculations
upon coordination of the olefin moieties support the experimental results.
■ INTRODUCTION
Shortly after the first report on the isolation of a free N-
heterocyclic carbene (NHC) by Arduengo’s group,1 exploita-
tion of their potential in organometallic chemistry and catalysis
began. NHCs provide two major advantages for catalyst design:
ease in synthesis, which allows for structural tunability, and,
more importantly, a high electron σ-donor capacity ensuing
stronger metal−ligand bonds, thereby resulting in the
stabilization of highly reactive intermediates which could
enhance catalytic performances.2 Consequently, a myriad of
modifications within the basic NHC scaffold has been
undertaken in recent years.3 Particularly, a pendant donating
group may offer advantages for the improvement of catalytic
activity and the control of the selectivity outcome. In some
instances, functionalized NHCs can stabilize low-coordinate
highly reactive species through the formation of stable chelates
or pincers, while in others, they behave as hemilabile ligands
which enable the interaction of the substrates and the metal
center in saturated derivatives, with relevant implications in
catalytic activity.4 In this context, several NHC-functionalized
metal complexes ranging from alkenyl,5 amine,6 pyridyl,7
phosphine,8 carbonyl,9 alcohol,10 ether,11 or thio,12 among
others,13 have been reported.
Coumarins consist of fused α-pyron and benzene rings. Their
utility spans luminescence, polymeric materials, and biological
applications.14−17 Introduction of an electron-releasing group at
7-position and/or an electron-withdrawing substituent at 3-
position results in fluorescence enhancement which has been
applied for laser dyes and sensors.14 Coumarin derivatives have
also been shown a broad spectrum of biological activity,15
including anti-HIV,15a anticancer,15b and enzyme inhibition.15c,d
Well-known clinically used examples include warfarin as
anticoagulant16 or novobiocin as antibiotic.17 Due to a
synergistic effect, a coumarin framework has been incorporated
into different ligands for a wide array of metal complexes that
results in the improvement of biological18 or photophysical
properties.19 Moreover, coumarin-based complexes have also
found application as catalysts for cross-coupling,20 polymer-
ization,21 or olefin metathesis,22 but to the best of our
knowledge, coumarin-containing rhodium complexes have not
been reported so far.
In recent years, our research interests have been focused in
the development of the organometallic chemistry of Rh−NHC
complexes23 and their catalytic applications.24 We envisage that
modification of the NHC framework by the introduction of a
pendant coumarin moiety that can potentially interact with the
metallic center or a substrate through its unsaturated lactonic
ring entails interesting implications on catalytic applications
(Chart 1).25,26 In this regard, biological applications of
coumarin-functionalized NHC silver and gold complexes have
been previously studied by some of us and others.27 Now, we
aim to synthesize for the first time coumarin-substituted NHC
rhodium complexes and study their coordination behavior.
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■ RESULTS AND DISCUSSION
Synthesis of Coumarin−NHC Rhodium(I) Complexes.
Coumarin-tethered azolium salts 1 [1-R,3̅-{(7,8-dimethyl-2H-
chromen-2-one-4-yl)methyl}benzimidazolium chloride = BzI-
CouRHCl] and 2 [1-R,3 ̅-{(7,8-dimethyl-2H-chromen-2-one-4-
yl)methyl}imidazolium chloride = ICouRHCl] were prepared in
good to excellent yields as previously described27b starting from
4-chloromethyl-7,8-dimethyl coumarin28 and the correspond-
ing nitrogenated heterocycle (Scheme 1). The synthesis of
rhodium coumarin−NHC complexes was accomplished
directly by treatment of 1 or 2 with [Rh(μ-OCH3)(cod)]2
(cod = 1,5-cyclooctadiene) in THF at room temperature to
yield RhCl(BzICouR)(cod) (3) or RhCl(ICouR)(cod) (4), thus
avoiding a preliminary deprotonation step or the preparation of
the corresponding Ag−NHC complexes. The formation of
benzimidazolin-2-carbene complexes 3 required a reaction time
of 16 h. However, similar reaction conditions for the
preparation of imidazolin-2-carbene species 4 resulted in the
formation of an additional minor species (see below). Shorter
reaction time (4 h) and filtration from THF allowed the
isolation of complexes 4 in a pure form. As far as we know, 3
and 4 constitute the first rhodium complexes bearing a
coumarin-functionalized NHC ligand.
The solid state structures of 3b, 3c, and 4a have been
determined by X-ray diffraction analyses on single crystals
obtained by slow evaporation of CDCl3 solutions (Figure 1, see
the Supporting Information for 3b). For all complexes, a
distorted square-planar geometry around the metal center is
observed. The rhodium−carbene separations lie in the range
t y p i c a l l y o b s e r v e d f o r a R h−NHC s i n g l e
bond.4c,5c,g,h,7c,9,12b,13a,f,23,24 Furthermore, a slightly distorted
coordination of the carbene moiety is reflected in the in-plane
bending of the nitrogenated plane with respect to the Rh−
NHC axis, described as the yaw angle (ψ 7.4°, 3c; 9.0°,
4a).29,24f A slightly shorter Rh−NHC distance is observed in
benzimidazolin−NHC complex 3c compared to that in
imidazolin−NHC complex 4a, {Rh−C(1) 2.010(2) (3c),
2.0337(19) Å (4a)}. The higher trans-influence of the carbene
versus the chlorido ligand results in a longer separation from
the metal center for the coordinated double bond opposite to
the NHC ligand {Rh−ct[C(36)−C(37)] = 2.1054(2) vs Rh−
ct[C(32)−C(33)] = 1.9963(2) for 3c or Rh−ct[C(31)−
C(32)] = 2.0892(2) vs Rh−ct[C(27)−C(28)] = 1.9921(2)
for 4a (ct[C(X)−C(Y)], centroid of the C(X)−C(Y) bond)}.
The NMR spectroscopic data show that the structures of 3
and 4 in solution are similar to those found in the solid state. A
prototypical signal for the identification of the coumarin moiety
is the olefinic proton of the lactonic ring, which appears as a
singlet between δ 5.65 and 5.97 ppm. In stark contrast to
azolium salts 1 and 2, the methylene protons connecting NHC
Chart 1. Potential Interactions of a Coumarin-
Functionalized NHC−Rh Framework
Scheme 1. Synthesis of Coumarin-Functionalized NHC−Rh
Complexes 3 and 4
Figure 1. ORTEP views of 3c and 4a. Ellipsoids are at 50%
probability, and hydrogen atoms are omitted for clarity. Selected bond
lengths (Å) and angles (deg): 3c: Rh−C(1) 2.010(2), Rh−ct[C(32)−
C(33)] 1.9963(2), Rh−ct[C(36)−C(37)] 2.1054(2), Rh−Cl(1)
2.3814(6), C(3)−C(8) 1.396(3), C(32)−C(33) 1.399(3), C(36)−
C(37) 1.371(3), C(1)−Rh−Cl(1) 86.34(6), C(1)−Rh−ct[C(32)−
C(33)] 94.03(6), C(1)−Rh−ct[C(36)−C(37)] 175.92(6), Cl(1)−
Rh−ct[C(32)−C(33)] 177.07(2); 4a: Rh−C(1) 2.0337(19), Rh−
ct[C(27)−C(28)] 1.9921(2), Rh−ct[C(31)−C(32)] 2.0892(2), Rh−
Cl(1) 2.3942(5), C(3)−C(4) 1.340(3), C(27)−C(28) 1.400(3),
C(31)−C(32) 1.374(3), C(1)−Rh−Cl(1) 87.88(5), C(1)−Rh−ct-
[C(27)−C(28)] 94.09(5), C(1)−Rh−ct[C(31)−C(32)] 177.08(6),
Cl(1)−Rh−ct[C(27)−C(28)] 173.13(2). ct[C(X)−C(Y)], centroid
of the C(X)−C(Y) bond.
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and the coumarin framework are diastereotopic, as a
consequence of the coordination to the metal center. Thus,
two doublets with a geminal coupling constant of about 18 Hz
are displayed at around 7.1 and 5.6 ppm for complexes 3. The
separation between methylene signals is reduced to about 0.8
ppm in imidazolin-2-carbene complexes 4. Furthermore,
methylene protons of the benzyl substituents are also
diastereotopic but smaller separation are observed (Figure 2).
The differences between benzimidazolin- and imidazolin-2-
carbene complexes are also evident in the 13C{1H}-APT NMR
spectra. The signals corresponding to carbene carbon atoms of
3 appear as doublets around δ 198 ppm (JC−Rh ≈ 51 Hz),
whereas those for the imidazolin derivatives 4 are about 13 ppm
more shielded. Two pairs of doublets are observed for the η2-
alkene carbon atoms of cod ligand around 100 and 70 ppm,
which is in agreement with the lack of a plane of symmetry and
with a hindered rotation of the carbene ligand around the Rh−
C axis. The doublets around 100 ppm exhibit smaller coupling
constants {JC−Rh ≈ 11 (3), 7 (4) Hz)} than those around 70
ppm (JC−Rh ≈ 14 Hz); therefore, the former doublets are
ascribed to the double bond located opposite to the carbene
due to the higher trans-influence of NHC compared to that of
chlorido ligand.30b
Similar coumarin−NHC ligands have been previously
prepared,27 but their donor properties have not been studied
in detail. In this regard, IR spectroscopy is a valuable method
for describing the bonding situation of a NHC ligand within
rhodium bis-carbonyl complexes. Bubbling carbon monoxide
through a solution of 3a−c or 4a resulted in the replacement of
the cod ligand to yield the bis-carbonyl species RhCl-
(BzICouR)(CO)2 (5a−c) and RhCl(ICoubz)(CO)2 (6a),
respectively (Scheme 2). The values for the symmetric CO
stretching mode, 2083 cm−1 for 5a versus 2075 cm−1 for 6a,
gives TEP parameters similar to that found in related
symmetrically substituted azole carbenes, showing slightly
higher electro-donating capacity for imidazolin-carbenes.30
The substitution of the diolefin ligand by CO results in closer
resonances for the diasterotopic methylene protons in the 1H
NMR spectra. The more interesting feature of the 13C{1H}-
APT NMR spectra is the shielding of rhodium-carbene carbon
resonances by about 8−11 ppm compared to cod derivatives,
with concomitant reduction of the JC−Rh of about 10 ppm
(Figure 3). Two doublets at around δ 184 ppm (JC−Rh ≈ 53
Hz) and 181 ppm (JC−Rh ≈ 73 Hz) were observed for the
nonequivalent carbonyl ligands, the first signal corresponding
to the CO located trans to the NHC. As observed for cod
complexes, the higher trans-influence of NHC elongates the
Rh−CO bond opposite to it, resulting in a decrease of the JC−Rh
coupling constant.
Synthesis of Pentacoordinated Bis-Coumarin−NHC
Rhodium(I) Complexes. During the preparation of com-
plexes 4, the formation of an additional minor species was
observed (see above). These species could be isolated from the
reaction mixture as white solids. Unexpectedly, the 1H NMR
spectra showed no resonances for the cod ligand and then the
formation of a bis-coumarin−NHC rhodium(I) species was
envisioned. These new complexes have been prepared in
acceptable yields (38−66%) by refluxing a THF solution of the
precursor [Rh(μ-OCH3)(cod)]2 and 2 equiv of the correspond-
ing azolium salts in the presence of sodium methoxide for 24 h
(Scheme 3). Cooling the reaction mixture gave the crude
compounds as white solids which were washed with cold THF
to remove unreacted cod complexes 3 and 4. Recrystallization
from CH2Cl2/hexane afforded the pentacoordinated bis-NHC
Figure 2. Comparison of the 1H NMR resonances of methylene
protons for 3a (top) and 4a (bottom).
Scheme 2. Synthesis of Coumarin-Functionalized NHC−Rh
Bis-carbonyl Complexes




Organometallics XXXX, XXX, XXX−XXX
C
derivatives RhCl(κ-C,η2-BzICouR)2 (7a−c) and RhCl(κ-C,η2-
ICouR)2 (8a,b). It is noticeable that the formation of 8
proceeds faster than that of 7, likely due to the slightly higher
electron-donor capacity of imidazolin-2-carbenes. Pentacoordi-
nate rhodium(I) complexes 7 and 8 are quite stable and
unreactive. For example, compound 7a does not react with
either methanol or aniline after 5 h at room temperature.
However, heating at 80 °C for 1 night resulted in
decomposition of the complex. Abstraction of the chlorido
ligand by treatment with thallium hexafluorophosphate resulted
in a mixture of unidentified species.
The solid state structures of 7b and 8b have been determined
by X-ray diffraction analyses on single crystals obtained by slow
evaporation of CH2Cl2 (7b) or CDCl3 (8b) solutions (Figure
4). For both complexes, the coordination polyhedron of the
rhodium atom is a distorted trigonal bipyramid31 (τ = 0.64 for
7b and τ = 0.65 for 8b) with the carbene carbon atoms in the
apical positions {C(1)−Rh−C(28) = 172.25(13) (7b), C(1)−
Rh−C(1)′ = 172.90(11) (8b)}. The η2-carbon−carbon bonds
of the coumarin moieties lie in the equatorial plane, disposed in
an in-plane fashion, in accordance to expectations based on
orbital energy for the more π-acceptor ligands.32 The
rhodium−carbene bond slightly elongates in comparison with
those in square-planar cod complexes {Rh−C(1) = 2.042(3) Å
in 7b vs 2.010(2) Å in 3c and Rh−C(1) = 2.0579(19) Å in 8b
vs 2.0337(19) Å in 4a}. This fact reasonably reflects the strain
within the κ-C,η2-olefin ligand, since generally that distance
shortens upon the formation of a chelate.5e Alternatively, the
possibility that the lengthening of the Rh(I)−NHC bond was
caused by a change in coordination number cannot be ruled
out. The chelate formation results in higher yaw angles for the
heterocyclic ring in 7b (ψ 12.4°) and 8b (ψ 12.2°) compared to
those in 3c (ψ 7.4°) and 4a (ψ 9.0°). In addition, the
elongation of the double bond within the lactonic ring, around
0.08 Å, is in accordance with a coordinated olefin but not
enough that the Rh(η2-CC) fragment should be considered a
metalacyclopropane. Remarkably, the κ-C,η2-CC coordination
of the NHC ligand gives rise to a chiral environment around
the metal center for both 7b and 8b. According to the skew line
system,33 the enantiomers shown in Figure 4 exhibit a Δ
configuration. Nevertheless, due to the centrosymmetric space-
groups of 7b (P21/n) and 8b (C2/c), both enantiomers Λ and
Δ are present in the unit cell. Further, different diasteroisomers
can form for configurations Λ and Δ of the metal center
depending on which enantioface of the C3C4 double bond of
the coumarin moiety coordinates to the metal center, namely,
3si,4re or 3re,4si. Notably, each coumarin wingtip coordinate by
the same 3si,4re enantioface in both 7b and 8b. Neither intra-
or intermolecular interactions have been observed between the
oxygen atom of the carbonyl groups and the metallic center.
The solid-state structure observed for 7b and 8b is
maintained in solution. As a consequence of the C2 symmetry
of the complexes, only one set of resonances are observed for
both NHC-coumarin ligands in the NMR spectra. Complex 8a
is quite insoluble in chlorinated solvents and only fairly soluble
in DMSO-d6 even at 90 °C, which prevents the observation of
some quaternary carbons in the 13C{1H}-APT NMR spectrum.
The coordination of the coumarin moiety is reflected in a shift
to a more shielded region of the signals corresponding to the
olefinic proton (H3) and the methylene protons connecting the
coumarin moiety to the NHC (H11), with concomitant
reduction on the geminal coupling constant (Figure 5). In
agreement with this coordination, the 13C{1H}-APT NMR
spectra display two doublets at about δ 73 ppm (JC−Rh ≈ 12
Hz) and 51 ppm (JC−Rh ≈ 7 Hz) corresponding to the
quaternary and CH olefinic carbon atoms, respectively. The
resonances corresponding to the carbene carbon atoms of 7
and 8 also appear shielded by about 10−15 compared to Rh−
cod derivatives. In addition, the JC−Rh values are reduced to
about 34 Hz, reflecting the lengthening of the Rh−NHC bond.
Derivatives 7 and 8 belong to the selected club of
pentacoordinated rhodium(I) complexes. In spite of the huge
development of Rh−NHC organometallic chemistry, examples
of this family remain scarce,5h,13a,34 likely due to the powerful
electron-donor ability of NHC ligands that favor a square-
planar environment over pentacoordinated structures. A
complex containing two ligands bearing an unsaturated pendant
group coordinated in a chelate fashion is unprecedented for
Scheme 3. Synthesis of Bis-Coumarin−NHC
Pentacoordinated RhI Complexes
Figure 4. ORTEP views of 7b and 8b. Ellipsoids are at 50%
probability. Hydrogen atoms and butyl substituent of NHC are
omitted for clarity. Selected bond lengths (Å) and angles (deg): 7b:
Rh−C(1) 2.042(3), Rh−C(28) 2.043(3), Rh−ct[C(11)−C(12)]
2.0525(3), Rh−ct[C(38)−C(39)] 2.0677(3), C(11)−C(12)
1.429(4), C(38)−C(39) 1.430(4), C(1)−Rh−C(28) 172.25(13),
ct[C(11)−C(12)]−Rh−ct[C(38)−C(39)] 133.52(1), Cl(1)−Rh−ct-
[C(11)−C(12)] 114.84(2), Cl(1)−Rh−ct[C(38)−C(39)] 111.65(2),
C(1)−Rh−ct[C(11)−C(12)] 79.29(9), C(1)−Rh−ct[C(38)−C(39)]
97.05(9), C(1)−Rh−Cl(1) 95.02(9), C(28)−Rh−Cl(1) 92.73(10);
8b: Rh−C(1) 2.0579(19), Rh−ct[C(7)−C(8)] 2.0513(1), C(7)−
C(8) 1.429(3), C(1)−Rh−C(1)′ 172.90(11), ct[C(7)−C(8)]−Rh−
ct[C(7)′−C(8)′] 133.82(10), Cl(1)−Rh−ct[C(7)−C(8)] 113.09(1),
C(1)−Rh−ct[C(7)−C(8)] 79.29(5), C(1)−Rh−ct[C(7)′−C(8)′]
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Rh−NHC systems, although similar examples have been
described in rhodium−phosphine and amine chemistry.35 It is
also worth noting that the formation of complexes 7 and 8
involves the replacement of a rather strong coordinating
diolefin such as cod by two trisubstituted carbon−carbon
double bonds bearing an electron-withdrawing group. Notably,
only the diastereoisomer in which both coumarin coordinates
by the 3si,4re enantioface is encountered for complexes 7 and 8.
Remarkably, this preferred coordination triggers that both
carbonyl groups were located at the same side of the chlorido
ligand, which might have interesting implications on potential
catalytic activity.
With the aim of evaluating the bonding strength of the η2-
lactonic ring and studying the competitive coordination with
other unsaturated functions, new precursors for NHC−
coumarin ligands bearing vinyl (2d) and allyl (1e) substituents
have been designed. Applying the synthetic protocol described
above, the η2-coumarin RhI-pentacoordinated complex RhCl(κ-
C,η2-ICouvin)2 (8d) was prepared from 2d and isolated as a
white solid in moderate yield (Scheme 4). Complex 8d is
sparely soluble in chlorinated solvents and was characterized in
DMSO-d6. The presence of uncoordinated vinyl group in 8d is
clearly established from the 1H NMR spectrum that shows a
typical deshielded doublet of doublets at δ 8.01 ppm and two
doublets at 5.37 and 4.79 ppm with JH−H of 16.0 Hz (trans), 9.0
Hz (cis) and 1.6 Hz (gem). Moreover, the coumarin olefinic
proton resonates at 3.64 ppm as a doublet with a small JH−Rh
(1.2 Hz), whereas a broad signal at δ 72.9 ppm and a doublet at
51.1 ppm (JC−Rh = 6.2 Hz) are observed in the
13C{1H}-APT
NMR spectrum, in agreement with a η2-coumarin coordination.
Certainly, this result is not surprising since a chelate vinyl−
NHC framework has not been described so far, although we
have observed a κ-N,η2-vinyl coordination for 1-vinylpyrazol
with a highly similar structure.24e
In contrast to 8d, treatment of the doubly functionalized
benzimidazolium salt 1e with [Rh(μ-OCH3)(cod)]2 in the
presence of sodium methoxide resulted in the formation of a η2-
allyl derivative RhCl(κ-C,η2-BzICouall)2 (9). The η
2-coordina-
tion of both allyl moieties within the NHC framework was
corroborated by an X-ray diffraction analysis on a single crystal
of 9 (Figure 6). Similar to 7b and 8b, a distorted trigonal
bipyramidal environment (τ 0.62) around the metal atom in 9
was observed. The axial positions are occupied by NHC carbon
atoms C(1) and C(27) {Figure 6, C(1)−Rh−C(27)
168.09(13)°}, whereas allyl and chlorido ligands occupy the
equatorial positions, rendering a chiral environment at the
metal center. The Δ configuration is shown in Figure 6;
nevertheless, as a consequence of the centrosymmetric P1 ̅ space
group, both configurations are present in the crystal. Also,
considering the Δ enantiomer, only the diasteroisomer
resulting from the coordination of rhodium to the 2si
Figure 5. 1H NMR spectra of 4b (top) and 8b (bottom).
Scheme 4. Competitive Coordination of η2-Coumarin
Moieties in Pentacoordinated Bis-NHC Rhodium(I)
Complexes
Figure 6. ORTEP view of 9. Ellipsoids are at 50% probability and
hydrogen atoms are omitted for clarity. Selected bond lengths (Å) and
angles (deg): Rh−C(1) 2.010(4), Rh−C(27) 2.031(3), Rh−ct-
[C(25)−C(26)] 2.0296(3), Rh−ct[C(51)−C(52)] 2.0341(3),
C(25)−C(26) 1.406(5), C(51)−C(52) 1.395(5), C(1)−Rh−C(27)
168.09(13), ct[C(25)−C(26)]−Rh−ct[C(51)−C(52)] 131.17(1),
Cl(1)−Rh−ct[C(25)−C(26)] 113.77(2), Cl(1)−Rh−ct[C(51)−
C(52)] 115.05(2), C(1)−Rh−ct[C(25)−C(26)] 81.95(9), C(1)−
Rh−ct[C(51)−C(52)] 91.30(9), C(1)−Rh−Cl(1) 96.72(9), C(27)−
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enantioface of the allyl moiety is observed. Notably similar yaw
angles are observed for the two NHC ligands (ψC(1) 11.0°,
ψC(27) 11.5°) in 9, but rhodium−carbon bond lengths are
different (Figure 6). These differences arise from the different
patterns of interatomic contacts observed for the two
nonequivalent NHC ligands of 9 (see the Supporting
Information).
The NMR data for 9 agree with the structure described in
the solid state. The C2 symmetry results in the appearance of
only one set of signals for the equivalent doubly functionalized
NHC ligands. Coordination of the allyl group is supported by
the observation of a set of shielded resonances at δ 3.01 ppm
(d, JH−H = 7.8 Hz) and 2.64 ppm (d, JH−H = 11.0 Hz),
corresponding to the terminal protons of the bonded olefin,
which correlate each other in the 1H−1H COSY NMR
spectrum and with a broad signal at 4.33 ppm ascribed to the
internal proton of the double bond. Moreover, the olefinic
proton of the coumarin moiety is observed at δ 5.46 ppm,
within the expected range for the unbonded moiety. In
addition, the two doublets at δ 59.3 ppm (JC−Rh = 12.7 Hz) and
49.2 ppm (JC−Rh = 5.6 Hz) in the
13C{1H}-APT NMR
spectrum, correlate respectively with the CH and CH2
proton resonances of the coordinated allyl moiety in the
1H−13C HSQC NMR experiment. The carbene carbon atom is
observed as a doublet at δ 195.6 ppm with a JC−Rh coupling
constant of 35.7 Hz.
DFT Calculations on the Coordination of the Olefin
Moiety. In order to shed light onto the coordination behavior
of coumarin-functionalized NHC ligand, a DFT computational
analysis has been carried out using the B3LYP method. Full
NHC-coumarin and cod, have been explicitly considered.
Substitution of cod by a coumarin-functionalized NHC ligand
results in a net stabilization by 6.8 kcal mol−1, in accordance
with the experimental results (Figure 7). As discussed
previously, only the diastereoisomer in which both coumarin
coordinates by the 3si,4re enantioface is encountered for
complexes 7 and 8.
Putative complex 8b′, with one coumarin coordinated by
3si,4re and the other by 3re,4si, has been calculated to be less
stable than 8b by 4.8 kcal mol−1 (Figure 8), probably as a
consequence of a more crowded environment around the metal
center. Moreover, a minimum for the isomer bearing both
coumarin ligands coordinated by its 3re,4si enantioface could
not be located in the potential energy surface.
Coordination of a rather electron-poor trisubstituted olefin
fragment found in complexes 7 and 8 is intriguing. The allyl
substituent in the coumarin−NHC framework competes for the
coordination site at the metal center resulting in the formation
of 9. DFT calculations are in agreement with this experimental
result, showing that 9 is predicted to be 14.7 kcal mol−1 more
stable than putative complex 9′ bearing the coordinated
coumarin moieties (Figure 9). Derivative 9′′ with a “mixed”
set of coordinated olefin moieties is also 6.8 kcal mol−1 less
stable than 9. Similar to 7 and 8, both allyl fragments within 9
coordinate by the same 2si enantioface. Coordination either by
two 2re enantiofaces or by one 2si and one 2re enantionfaces
results in disfavored species (see the Supporting Information).
■ CONCLUSION
The synthesis of coumarin-functionalized NHC−rhodium
complexes has been described for the first time. Introduction
of coumarin-substituted benzimidazolin and imidazolin-carbene
ligands can be achieved easily from [Rh(μ-OCH3)(cod)]2
without the need of isolation of free carbene or the use of
silver salts. The electron-donor ability of the new ligands,
determined from bis-carbonyl rhodium complexes, is similar to
that found for related azole carbenes, showing a slightly higher
electron-donor capacity for imidazolin-carbenes. Trigonal
bypiramidal pentacoordinated bis-coumarin−NHC complexes
RhCl(κ-C,η2-NHC)2 have been prepared by heating the
rhodium-cod derivatives in the presence of coumarin-azolium
salts and sodium methoxide. It is noticeable that coordination
of the carbon−carbon double bond of the lactonic ring in these
Figure 7. Energy profile for the formation of 8b from 4b and
coumarin-functionalized NHC (ΔG, kcal mol−1).
Figure 8. DFT-computed energies for coumarin coordination by
different enantiofaces in RhCl(κ−C,η2-ICoubu)2 (ΔG, kcal mol−1).
Figure 9. DFT-computed energies for coordination of coumarin
versus allyl moieties (ΔG, kcal mol−1).
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complexes takes place by the same enantioface for both NHC
ligands, resulting in a particular disposition of carbonyl groups
and chlorido ligand of potential interest for catalysis. Studies on
doubly functionalized coumarin−NHC derivatives have shown
the preferential diastereoselective coordination of an allyl
wingtip over the lactonic ring. DFT calculations on the
coordination of the olefin moieties in these complexes support
the experimental results. An important effort is currently being
done in our laboratories in order to develop the potential of
these complexes for catalytic, biological, or photophysical
applications.
■ EXPERIMENTAL SECTION
General Considerations. All reactions were carried out with
rigorous exclusion of air using Schlenk tube techniques. The reagents
were purchased from commercial sources and were used as received. 4-
Chloromethyl-7,8-dimethyl-2H-chromene-2-one28 and [Rh(μ-OCH3)-
(cod)]2
36 were synthesized by the procedures described in literature.
Organic solvents were dried by standard methods and distilled under
argon prior to use or obtained oxygen- and water-free from a Solvent
Purification System (Innovative Technologies). Chemical shifts
(expressed in parts per million (ppm)) are referenced to residual
solvent peaks (1H, 13C{1H}). Coupling constants, J, are given in Hz.
Spectral assignments were achieved by combination of 1H−1H COSY,
13C{1H}-APT and 1H−13C HSQC/HMBC experiments. H, C, and N
analysis were carried out in a PerkinElmer 2400 CHNS/O analyzer.
Infrared spectra were recorded on a PerkinElmer Spectrum 100
spectrometer, using an Universal ATR Sampling Accessory (neat
samples).
RhCl(BzICoubz)(cod) (3a). A yellow solution of [Rh(μ-OCH3)-
(cod)]2 (106 mg, 0.2 mmol) in 20 mL of THF was treated with 1a
(173 mg, 0.4 mmol) and was stirred at room temperature for 16 h.
After this period, the solution was filtered through Celite and
concentrated to ca. 1 mL. Then, n-hexane was added to induce the
precipitation of an orange solid which was washed with n-hexane (3 ×
5 mL) and dried in vacuo. Yield: 190 mg (74%). Anal. Calcd for
C34H34N2O2RhCl: C, 63.71; H, 5.35; N, 4.37. Found: C, 64.07; H,
5.44; N, 4.06. 1H NMR (400 MHz, CDCl3, 298 K): δ 7.76 (d, JH−H =
8.1, 1H, H5), 7.4−7.0 (11H, H6,11,14−17, HPh), 6.28 and 6.17 (both d,
JH−H = 15.8, 2H, NCH2Ph), 5.73 (s, 1H, H3), 5.70 (d, JH−H = 18.5, 1H,
H11), 5.14 and 3.39 (both m, 4H, CHcod), 2.49 (s, 3H, H9), 2.45 (s,
3H, H10), 2.4−1.7 (m, 8H, CH2cod). 13C{1H}-APT NMR (100.4 MHz,
CDCl3, 298 K): δ 199.1 (d, JC−Rh = 51.2, Rh−CNHC), 160.9 (CO),
151.9 (s, C8a), 150.9 (s, C4), 142.9 (s, C7), 135.8 (s, Cq‑Ph), 135.0 and
134.9 (both s, C12,13), 129.2 (s, Cm‑Ph), 128.2 (s, Cp‑Ph), 127.2 (s,
Co‑Ph), 126.5 (s, C6), 125.6 (s, C8), 123.4 (s, C15,16), 120.5 (s, C5),
115.1 (s, C4a), 111.6 and 110.2 (both s, C14,17), 111.2 (s, C3), 101.4
and 101.3 (both d, JC−Rh = 11.8, CHcod), 69.6 (d, JC−Rh = 14.1, 
CHcod), 53.2 (s, NCH2Ph), 49.2 (s, C11), 33.2, 32.7, 28.8, and 28.5 (all
s, CH2cod), 20.7 (C9), 11.9 (C10).
RhCl(BzICoubu)(cod) (3b). The complex was prepared as
described for 3a starting from [Rh(μ-OCH3)(cod)]2 (106 mg, 0.2
mmol) and 1b (159 mg, 0.4 mmol). Yield: 170 mg (70%). Anal. Calcd
for C31H36N2O2RhCl: C, 61.34; H, 5.98; N, 4.62. Found: C, 61.03; H,
5.72; N, 4.37. 1H NMR (400 MHz, CDCl3, 298 K): δ 7.73 (d, JH−H =
8.1, 1H, H5), 7.38 (d, JH−H = 8.1, 1H, H17), 7.30 (d, JH−H = 8.1, 1H,
H6), 7.25 (m, 1H, H16), 7.21 and 5.62 (both d, JH−H = 18.1, 2H, H11),
7.16 (m, 1H, H15), 7.03 (d, JH−H = 8.1, 1H, H14), 5.65 (s, 1H, H3),
5.16, 5.09, 4.44, and 3.38 (all m, 4H, CHcod), 4.86 (m, 2H,
NCH2CH2), 2.48 (s, 3H, H9), 2.43 (s, 3H, H10), 2.4−1.7 (m, 10H,
CH2cod, NCH2CH2), 1.62 (m, 2H, CH2CH3), 1.13 (t, JH−H = 7.4, 3H,
CH2CH3).
13C{1H}-APT NMR (100.4 MHz, CDCl3, 298 K): δ 197.8
(d, JC−Rh = 51.2, Rh−CNHC), 160.9 (CO), 151.9 (s, C8a), 151.0 (s,
C4), 142.9 (s, C7), 134.9 and 134.7 (both s, C12,13), 126.4 (s, C6),
125.5 (s, C8), 123.2 (s, C15,16), 120.4 (s, C5), 115.1 (s, C4a), 111.2 (s,
C3), 110.6 (s, C17), 110.3 (s, C14), 101.0 and 100.9 (both d, JC−Rh =
9.5,CHcod), 69.5 and 68.8 (both d, JC−Rh = 14.6,CHcod), 49.1 (s,
C11), 48.9 (s, NCH2CH2), 33.4, 32.7, 29.1, and 28.3 (all s, CH2cod),
31.8 (s, NCH2CH2), 20.6 (s, CH2CH3), 20.5 (C9), 13.9 (s, CH2CH3),
11.9 (C10).
RhCl(BzICoutol)(cod) (3c). The complex was prepared as described
for 3a starting from [Rh(μ-OCH3)(cod)]2 (106 mg, 0.2 mmol) and 1c
(178 mg, 0.4 mmol). Yield: 200 mg (76%). Anal. Calcd for
C35H36N2O2RhCl: C, 64.18; H, 5.54; N, 4.28. Found: C, 63.88; H,
5.13; N, 4.32. 1H NMR (400 MHz, CDCl3, 298 K): δ 7.76 (d, JH−H =
8.1, 1H, H5), 7.3−7.1 (6H, H6,11, Htol), 7.08 (m, 4H, H14−17), 6.24 and
6.12 (both d, JH−H = 15.6, 2H, NCH2Ph), 5.73 (s, 1H, H3), 5.70 (d,
JH−H = 18.5, 1H, H11), 5.14 and 3.39 (both m, 4H, CHcod), 2.49 (s,
3H, H9), 2.44 (s, 3H, H10), 2.4−1.7 (m, 8H, CH2cod), 2.35 (s, 3H,
Metol).
13C{1H}-APT NMR (100.4 MHz, CDCl3, 298 K): δ 198.9 (d,
JC−Rh = 50.9, Rh−CNHC), 160.9 (CO), 151.9 (s, C8a), 151.0 (s, C4),
142.9 (s, C7), 137.9 (s, CqMe), 135.0 and 134.9 (both s, C12,13), 132.7
(s, CqCH2CN), 129.8 and 127.1 (both s, CHtol), 126.5 (s, C6), 125.6
(s, C8), 123.3 (s, C15,16), 120.5 (s, C5), 115.1 (s, C4a), 111.7 and 110.2
(both s, C14,17), 111.2 (s, C3), 101.3 and 101.2 (both d, JC−Rh = 11.3,CHcod), 69.6 (d, JC−Rh = 14.4,CHcod), 53.1 (s, NCH2Ph), 49.2 (s,
C11), 33.2, 32.6, 28.9, and 28.3 (all s, CH2cod), 21.4 (s, Metol), 20.7
(C9), 11.9 (C10).
RhCl(ICoubz)(cod) (4a). A yellow solution of [Rh(μ-OCH3)-
(cod)]2 (106 mg, 0.2 mmol) in 20 mL of THF was treated with 2a
(152 mg, 0.4 mmol) and stirred at room temperature for 4 h. After this
period, the mixture was cooled into an ice bath, filtered through Celite,
and concentrated to ca. 1 mL. Then, n-hexane was added to induce the
precipitation of a yellow solid which was washed with n-hexane (3 × 5
mL) and dried in vacuo. Yield: 190 mg (80%). Anal. Calcd for
C30H32N2O2RhCl: C, 60.97; H, 5.46; N, 4.74. Found: C, 60.88; H,
5.30; N, 4.91. 1H NMR (500 MHz, CDCl3, 298 K): δ 7.68 (d, JH−H =
8.1, 1H, H5), 7.4−7.3 (5H, HPh), 7.22 (d, JH−H = 8.1, 1H, H6), 6.85
and 6.77 (both d, JH−H = 2.0, 2H, H12,13), 6.52 and 5.67 (both d, JH−H
= 17.2, 2H, H11), 5.97 (s, 1H, H3), 5.91 and 5.76 (both d, JH−H = 14.9,
2H, NCH2Ph), 5.07, 3.35, and 3.28 (all m, 4H, CHcod), 2.43 (s, 3H,
H9), 2.40 (s, 3H, H10), 2.4−1.7 (m, 8H, CH2cod). 13C{1H}-APT NMR
(100.4 MHz, CDCl3, 298 K): δ 185.6 (d, JC−Rh = 52.1, Rh−CNHC),
160.9 (CO), 151.9 (s, C8a), 151.8 (s, C4), 142.8 (s, C7), 136.1 (s,
Cq‑Ph), 129.1 (s, Cm‑Ph), 128.5 (s, Cp‑Ph), 128.3 (s, Co‑Ph), 126.5 (s, C6),
125.3 (s, C8), 121.8 and 121.6 (both s, C12,13), 121.0 (s, C5), 115.1 (s,
C4a), 112.2 (s, C3), 99.8 and 99.7 (both d, JC−Rh = 7.0,CHcod), 69.0
and 68.7 (both d, JC−Rh = 14.3,CHcod), 54.9 (s, NCH2Ph), 51.3 (s,
C11), 33.1, 32.9, 28.8, and 28.7 (all s, CH2cod), 20.6 (C9), 11.8 (C10).
RhCl(ICoubu)(cod) (4b). The complex was prepared as described
for 4a starting from [Rh(μ-OCH3)(cod)]2 (106 mg, 0.2 mmol) and 2b
(139 mg, 0.4 mmol). Yield: 140 mg (63%). Anal. Calcd for
C27H34N2O2RhCl: C, 58.23; H, 6.15; N, 5.03. Found: C, 57.88; H,
6.43; N, 5.41. 1H NMR (400 MHz, CDCl3, 298 K): δ 7.66 (d, JH−H =
8.1, 1H, H5), 7.22 (d, JH−H = 8.1, 1H, H6), 6.96 and 6.86 (both d, JH−H
= 2.0, 2H, H12,13), 6.57 and 5.60 (both d, JH−H = 17.4, 2H, H11), 5.90
(s, 1H, H3), 5.03, 3.32, and 3.27 (all m, 4H, CHcod), 4.55 (m, 2H,
NCH2CH2), 2.43 (s, 3H, H9), 2.40 (s, 3H, H10), 2.4−1.7 (m, 10H,
CH2cod, NCH2CH2), 1.52 (m, 2H, CH2CH3), 1.03 (t, JH−H = 7.4, 3H,
CH2CH3).
13C{1H}-APT NMR (100.4 MHz, CDCl3, 298 K): δ 183.8
(d, JC−Rh = 51.1, Rh−CNHC), 161.3 (CO), 152.5 (s, C8a), 151.4 (s,
C4), 142.9 (s, C7), 126.5 (s, C6), 125.2 (s, C8), 121.5 and 121.2 (both
s, C12,13), 120.7 (s, C5), 114.7 (s, C4a), 111.3 (s, C3), 99.1 and 99.2
(both d, JC−Rh = 6.5, = CHcod), 68.7 and 68.5 (both d, JC−Rh = 14.3,
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CHcod), 51.0 (s, C11), 50.7 (s, NCH2CH2), 33.2, 32.7, 28.9, and 28.6
(all s, CH2cod), 33.0 (s, NCH2CH2), 20.8 (C9), 20.1 (s, CH2CH3), 14.0
(s, CH2CH3), 11.9 (C10).
RhCl(ICouvin)(cod) (4d). The complex was prepared as described
for 4a starting from [Rh(μ-OCH3)(cod)]2 (106 mg, 0.2 mmol) and
2d (127 mg, 0.4 mmol). Yield: 110 mg (52%). Satisfactory elemental
analysis could not be obtained. HRMS (ESI) m/z Calcd for
RhC25H28N2O2 (M − Cl−): 491.1200. Found: 491.1197. 1H NMR
(400 MHz, CDCl3, 298 K): δ 8.15 (dd, JH−H = 15.8, 8.7, 1H, NCH
CH2), 7.66 (d, JH−H = 8.3, 1H, H5), 7.30 (d, JH−H = 2.0, 1H, H13), 7.23
(d, JH−H = 8.3, 1H, H6), 6.92 (d, JH−H = 2.0, 1H, H12), 6.57 and 5.63
(both d, JH−H = 17.4, 2H, H11), 5.89 (s, 1H, H3), 5.38 (dd, JH−H = 15.8,
1.8, 1H, NCHCH2), 5.12 (dd, JH−H = 8.7, 1.8, 1H, NCHCH2),
5.02, 3.38, and 3.20 (all m, 4H, CHcod), 2.42 (s, 3H, H9), 2.38 (s, 3H,
H10), 2.4−1.7 (m, 8H, CH2cod). 13C{1H}-APT NMR (100.4 MHz,
CDCl3, 298 K): δ 187.6 (d, JC−Rh = 51.5, Rh−CNHC), 161.1 (CO),
151.7 (s, C8a), 151.4 (s, C4), 143.0 (s, C7), 133.7 (s, NCHCH2),
126.6 (s, C6), 125.2 (s, C8), 121.8 (s, C12), 120.8 (s, C5), 117.9 (s,
C13), 114.6 (s, C4a), 111.6 (s, C3), 102.4 (s, NCHCH2), 100.2 and
100.0 (both d, JC−Rh = 6.8, CHcod), 70.1 and 68.8 (both d, JC−Rh =
14.4, CHcod), 51.5 (s, C11), 33.00, 32.7, 28.8, and 28.6 (all s,
CH2cod), 20.8 (C9), 11.9 (C10).
RhCl(BzICoubz)(CO)2 (5a). Carbon monoxide was bubbled
through an orange solution of 3a (100 mg, 0.16 mmol) in 20 mL of
THF at room temperature for 1 h. Then, the solution was filtered
through Celite and the filtrate concentrated to ca. 1 mL. Addition of n-
hexane induced the precipitation of an orange solid which was washed
with n-hexane (3 × 5 mL) and dried in vacuo. Yield: 70 mg (73%).
Anal. Calcd for C28H22N2O4RhCl: C, 57.11; H, 3.77; N, 4.76. Found:
C, 56.83; H, 3.56; N, 4.68. IR (cm−1): 2083 ν(CO)sym, 2010
ν(CO)asym, 1735 ν(CO)coumarin. 1H NMR (500 MHz, CDCl3, 298
K): δ 7.58 (d, JH−H = 8.0, 1H, H5), 7.4−7.2 (10H, H6,14−17, HPh), 6.54
and 5.73 (both d, JH−H = 18.0, 2H, H11), 5.95 (m, 2H, NCH2Ph), 5.62
(s, 1H, H3), 2.46 (s, 3H, H9), 2.43 (s, 3H, H10).
13C{1H}-APT NMR
(125.6 MHz, CDCl3, 298 K): δ 188.4 (d, JC−Rh = 43.6, Rh−CNHC),
184.7 (d, JC−Rh = 53.7, Rh−COtrans‑NHC), 181.6 (d, JC−Rh = 73.8, Rh−
COcis‑NHC), 160.5 (CO), 152.0 (s, C8a), 148.9 (s, C4), 142.9 (s, C7),
134.6 (s, Cq‑Ph), 134.5 and 134.4 (both s, C12,13), 129.3 (s, Cm‑Ph),
128.7 (s, Cp‑Ph), 127.6 (s, Co‑Ph), 126.4 (s, C6), 125.7 (s, C8), 124.7 and
124.6 (both s, C15,16), 120.3 (s, C5), 115.0 (s, C4a), 112.4 and 111.0
(both s, C14,17), 111.6 (s, C3), 53.5 (s, NCH2Ph), 48.9 (s, C11), 20.6
(C9), 11.9 (C10).
RhCl(BzICoubu)(CO)2 (5b). The complex was prepared as
described for 5a starting from 3b (100 mg, 0.18 mmol). Yield: 80
mg (82%). Anal. Calcd for C25H24N2O4RhCl: C, 54.12; H, 4.36; N,
5.05. Found: C, 54.10; H, 4.11; N, 5.39. IR (cm−1): 2076 ν(CO)sym,
1995 ν(CO)asym, 1737 ν (CO)coumarin. 1H NMR (300 MHz, CDCl3,
298 K): δ 7.53 (m, 2H, H5,17), 7.41 (m, 1H, H16), 7.32 (m, 1H, H15),
7.25 (d, JH−H = 8.0, 1H, H6), 7.21 (d, JH−H = 8.1, 1H, H14), 6.49 and
5.67 (both d, JH−H = 17.9, 2H, H11), 5.54 (s, 1H, H3), 4.76 and 4.57
(both m, 2H, NCH2CH2), 2.46 (s, 3H, H9), 2.41 (s, 3H, H10), 2.06
(m, 2H, NCH2CH2), 1.57 (m, 2H, CH2CH3), 1.06 (t, JH−H = 7.3, 3H,
CH2CH3).
13C{1H}-APT NMR (75.1 MHz, CDCl3, 298 K): δ 187.3
(d, JC−Rh = 43.0, Rh−CNHC), 184.9 (d, JC−Rh = 54.0, Rh−COtrans‑NHC),
182.1 (d, JC−Rh = 73.3, Rh−COcis‑NHC), 160.5 (CO), 152.0 (s, C8a),
149.1 (s, C4), 142.7 (s, C7), 134.4 (s, C12), 134.3 (s, C13), 126.3 (s,
C6), 125.7 (s, C8), 124.5 and 124.4 (both s, C15,16), 120.2 (s, C5),
115.0 (s, C4a), 111.6 (s, C17), 111.5 (s, C3), 111.0 (s, C14), 49.2 (s,
C11), 48.7 (s, NCH2CH2), 31.9 (s, NCH2CH2), 20.6 (C9), 20.4 (s,
CH2CH3), 13.9 (s, CH2CH3), 11.9 (C10).
RhCl(BzICoutol)(CO)2 (5c). The complex was prepared as
described for 5a starting from 3c (100 mg, 0.15 mmol). Yield: 75
mg (83%). Anal. Calcd for C29H24N2O4RhCl: C, 57.78; H, 4.01; N,
4.65. Found: C, 57.61; H, 4.18; N, 4.47. IR (cm−1): 2081 ν(CO)sym,
2003 ν(CO)asym, 1735 ν(CO)coumarin. 1H NMR (400 MHz, CDCl3,
298 K): δ 7.56 (d, JH−H = 8.2, 1H, H5), 7.4−7.2 (9H, H6,14−17, HPh),
6.54 and 5.73 (both d, JH−H = 18.4, 2H, H11), 5.90 (m, 2H, NCH2Ph),
5.54 (s, 1H, H3), 2.47 (s, 3H, H9), 2.41 (s, 3H, H10). 2.34 (s, 3H,
Metol).
13C{1H}-APT NMR (100.4 MHz, CDCl3, 298 K): δ 187.3 (d,
JC−Rh = 43.5, Rh−CNHC), 184.6 (d, JC−Rh = 54.4, Rh−COtrans‑NHC),
181.5 (d, JC−Rh = 74.3, Rh−COcis‑NHC), 160.9 (CO), 151.6 (s, C8a),
149.2 (s, C4), 143.0 (s, C7), 138.4 (s, CqMe), 134.2 and 134.0 (both s,
C12,13), 131.3 (s, CqCH2CN), 129.9 and 127.2 (both s, CHtol), 126.4
(s, C6), 125.6 (s, C8), 124.6 (s, C15,16), 120.2 (s, C5), 114.7 (s, C4a),
112.3 and 110.9 (both s, C14,17), 110.8 (s, C3), 53.1 (s, NCH2Ph), 48.5
(s, C11), 21.4 (s, Metol), 20.8 (C9), 11.8 (C10).
RhCl(ICoubz)(CO)2 (6a). The complex was prepared as described
for 5a starting from 4a (100 mg, 0.17 mmol). Yield: 70 mg (71%).
Anal. Calcd for C24H20N2O4RhCl: C, 53.50; H, 3.74; N, 5.20. Found:
C, 53.12; H, 4.08; N, 5.19. IR (cm−1): 2075 ν(CO)sym, 1994
ν(CO)asym, 1724 ν (CO)coumarin. 1H NMR (400 MHz, CD2Cl2, 233
K): δ 7.46 (d, JH−H = 7.9, 1H, H5), 7.4−7.3 (m, 5H, HPh), 7.18 (d,
JH−H = 7.9, 1H, H6), 7.01 and 7.03 (both d, JH−H = 2.0, 2H, H12,13),
5.97 and 5.52 (both d, JH−H = 17.8, 2H, H11), 5.70 (s, 1H, H3), 5.64
and 5.46 (both d, JH−H = 15.3, 2H, NCH2Ph), 2.39 (s, 3H, H9), 2.34
(s, 3H, H10).
13C{1H}-APT NMR (100.4 MHz, CD2Cl2, 298 K): δ
186.0 (d, JC−Rh = 54.4, Rh−COtrans‑NHC), 182.8 (d, JC−Rh = 73.5, Rh−
COcis‑NHC), 177.4 (d, JC−Rh = 44.1, Rh−CNHC), 160.7 (CO), 152.3
(s, C8a), 150.1 (s, C4), 143.2 (s, C7), 136.0 (s, Cq‑Ph), 129.6 (s, Cm‑Ph),
129.2 (s, Cp‑Ph), 128.9 (s, Co‑Ph), 126.5 (s, C6), 125.7 (s, C8), 123.2 and
123.1 (both s, C12,13), 121.1 (s, C5), 115.5 (s, C4a), 113.6 (s, C3), 55.8
(s, NCH2Ph), 51.2 (s, C11), 20.7 (C9), 12.0 (C10).
RhCl(κ-C,η2-BzICoubz)2 (7a). A yellow solution of [Rh(μ-OCH3)-
(cod)]2 (106 mg, 0.2 mmol) in 20 mL of THF was treated with 1a
(356 mg, 0.8 mmol) and NaOCH3 (22 mg, 0.4 mmol) and heated at
70 °C for 24 h. After this period, the mixture was cooled to 0 °C which
resulted in the formation of a precipitate. The mother liquor was
removed and the solid washed with cold THF (2 × 5 mL). Then, the
solid was dissolved in 20 mL of CH2Cl2 and filtered through Celite.
The solution was concentrated to ca. 1 mL, and n-hexane was added to
induce the precipitation of a white solid which was washed with n-
hexane (3 × 5 mL) and dried in vacuo. Yield: 140 mg (38%). Anal.
Calcd for C52H44N4O4RhCl: C, 67.35; H, 4.78; N, 6.04. Found: C,
67.28; H, 4.75; N, 6.13. 1H NMR (400 MHz, CDCl3, 253 K) δ 7.73
(d, JH−H = 7.8, 2H, H5), 7.5−6.8 (20H, H6,14−17, HPh), 7.27 and 5.28
(both d, JH−H = 15.0, 4H, NCH2Ph), 4.42 (s, 2H, H3), 4.30 and 3.81
(both d, JH−H = 13.2, 4H, H11), 1.82 (s, 6H, H9), 1.40 (s, 6H, H10).
13C{1H}-APT NMR (100.4 MHz, CDCl3, 253 K): δ 184.7 (d, JC−Rh =
33.8, Rh−CNHC), 168.9 (CO), 146.8 (s, C8a), 138.6 (s, C7), 136.4
(s, Cq‑Ph), 134.3 and 132.0 (both s, C12,13), 128.5 and 128.4 (both s,
Co‑m‑Ph), 127.6 (s, Cp‑Ph), 124.5 (s, C8), 124.3 (s, C6), 123.2 and 123.1
(both s, C15,16), 120.6 (s, C4a), 119.1 (s, C5), 112.3 and 109.4 (both s,
C14,17), 73.8 (d, JC−Rh = 11.9, C4), 52.0 (d, JC−Rh = 7.6, C3), 51.9 (s,
NCH2Ph), 46.6 (s, C11), 20.1 (C9), 11.0 (C10).
RhCl(κ-C,η2-BzICoubu)2 (7b). The complex was prepared as
described for 7a starting from [Rh(μ-OCH3)(cod)]2 (106 mg, 0.2
mmol), 1b (317 mg, 0.8 mmol), and NaOCH3 (22 mg, 0.4 mmol).
Yield 160 mg (47%). Anal. Calcd for C46H48N4O4RhCl: C, 64.30; H,
5.63; N, 6.52. Found: C, 64.18; H, 5.32; N, 6.37. 1H NMR (400 MHz,
CDCl3, 253 K): δ 7.73 (d, JH−H = 8.3, 2H, H5), 7.37 (d, JH−H = 8.5,
2H, H17), 7.25 (m, 2H, H16), 7.16 (m, 2H, H15), 6.89 (d, JH−H = 8.3,
2H, H6), 7.86 (d, JH−H = 8.5, 2H, H14), 5.41 and 4.09 (both m, 4H,
NCH2CH2), 4.28 and 3.75 (both d, JH−H = 12.7, 4H, H11), 4.16 (s, 2H,
H3), 1.95 (m, 4H, NCH2CH2), 1.72 (s, 6H, H9), 1.57 (m, 4H,
NCH2CH2), 1.32 (s, 6H, H10), 1.03 (t, JH−H = 7.2, 6H, CH2CH3).
13C{1H}-APT NMR (100.4 MHz, CDCl3, 253 K): δ 184.5 (d, JC−Rh =
34.7, Rh−CNHC), 168.9 (CO), 146.5 (s, C8a), 138.1 (s, C7), 134.0
(s, C13), 131.8 (s, C12), 124.4 (s, C8), 124.1 (s, C6), 123.0 (s, C15),
123.1 (s, C16), 120.7 (s, C4a), 118.8 (s, C5), 111.4 (s, C17), 109.5 (s,
C14), 73.0 (d, JC−Rh = 11.7, C4), 51.6 (d, JC−Rh = 7.5, C3), 47.4 (s,
NCH2CH2), 46.6 (s, C11), 32.1 (s, NCH2CH2), 20.1 (s, CH2CH3),
20.0 (C9), 14.1 (s, CH2CH3), 11.0 (C10).
RhCl(κ-C,η2-BzICoutol)2 (7c). The complex was prepared as
described for 7a starting from [Rh(μ-OCH3)(cod)]2 (106 mg, 0.2
mmol), 1c (356 mg, 0.8 mmol), and NaOCH3 (22 mg, 0.4 mmol).
Yield: 170 mg (45%). Anal. Calcd for C54H48N4O4RhCl: C, 67.89; H,
5.06; N, 5.86. Found: C, 67.52; H, 4.97; N, 5.75. 1H NMR (400 MHz,
CDCl3, 253 K): δ 7.73 (d, JH−H = 8.0, 2H, H5), 7.5−6.8 (18H, H6,14−17,
HPh), 7.15 and 5.21 (both d, JH−H = 14.7, 4H, NCH2Ph), 4.40 (s, 2H,
H3), 4.30 and 3.83 (both d, JH−H = 13.2, 4H, H11), 2.24 (s, 6H, Metol),
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1.82 (s, 6H, H9), 1.41 (s, 6H, H10).
13C{1H}-APT NMR (100.4 MHz,
CDCl3, 253 K): δ 184.7 (d, JC−Rh = 34.3, Rh−CNHC), 168.7 (CO),
146.7 (s, C8a), 138.5 (s, C7), 137.1 (s, CqMe), 134.2 and 132.1 (both s,
C12,13), 133.5 (s, CqCH2CN), 129.1 and 128.4 (both s, CHtol), 124.5
(s, C8), 124.2 (s, C6), 123.1 and 123.0 (both s, C15,16), 120.7 (s, C4a),
119.1 (s, C5), 112.4 and 109.3 (both s, C14,17), 73.5 (d, JC−Rh = 11.6,
C4), 52.0 (d, JC−Rh= 7.2, C3), 51.7 (s, NCH2Ph), 46.6 (s, C11), 21.4 (s,
Metol), 20.0 (C9), 10.9 (C10).
RhCl(κ-C,η2-ICoubz)2 (8a). The complex was prepared as described
for 7a starting from [Rh(μ-OCH3)(cod)]2 (106 mg, 0.2 mmol), 2a
(305 mg, 0.8 mmol), and NaOCH3 (22 mg, 0.4 mmol). Yield: 210 mg
(63%). Satisfactory elemental analysis could not be obtained. HRMS
(ESI) m/z Calcd for RhC44H40N4O4 (M − Cl−): 791.2099. Found:
791.2082. 1H NMR (400 MHz, DMSO-d6, 363 K): δ 7.64 (d, JH−H =
8.0, 2H, H5), 7.50 (d, JH−H = 7.0, 4H, Ho‑Ph), 7.34 (vt, N = 14.7, 4H,
Hm‑Ph), 7.29 (t, JH−H = 7.0, 2H, Hp‑Ph), 7.12 (d, JH−H = 8.0, 2H, H6),
6.83 and 6.70 (both d, JH−H = 2.0, 4H, H12,13), 6.48 and 4.89 (both d,
JH−H = 14.3, 4H, NCH2Ph), 4.10 and 3.81 (both d, JH−H = 15.1, 4H,
H11), 3.84 (s, 2H, H3), 2.23 (s, 6H, H9), 2.05 (s, 6H, H10).
13C{1H}-
APT NMR (100.4 MHz, DMSO-d6, 363 K): δ 168.0 (CO), 147.7
(s, C8a), 138.2 (s, C7), 137.6 (s, Cq‑Ph), 129.5 and 128.6 (both s,
Co‑m‑Ph), 128.0 (s, Cp‑Ph), 124.7 (s, C6), 123.9 (s, C8), 122.0 and 119.6
(both s, C12,13), 121.6 (s, C4a), 120.2 (s, C5), 112.3 and 109.4 (both s,
C14,17), 52.6 (s, NCH2Ph), 49.6 (s, C11), 19.8 (C9), 11.4 (C10).
RhCl(κ-C,η2-ICoubu)2 (8b). The complex was prepared as
described for 7a starting from [Rh(μ-OCH3)(cod)]2 (106 mg, 0.2
mmol), 2b (277 mg, 0.8 mmol), and NaOCH3 (22 mg, 0.4 mmol).
Yield: 200 mg (66%). Anal. Calcd for C38H44N4O4RhCl: C, 60.12; H,
5.84; N, 7.38. Found: C, 59.70; H, 5.83; N, 7.10. 1H NMR (400 MHz,
CDCl3, 253 K): δ 7.46 (d, JH−H = 8.0, 1H, H5), 6.97 (d, JH−H = 8.0,
1H, H6), 6.63 and 6.49 (both d, JH−H = 1.8, 3H, H12,13), 5.03 and 3.85
(both m, 2H, NCH2CH2), 4.10 and 3.52 (both d, JH−H = 13.8, 2H,
H11), 3.91 (s, 1H, H3), 2.18 (s, 3H, H9), 1.96 (s, 3H, H10), 1.70 (m,
2H, NCH2CH2), 1.44 (m, 2H, NCH2CH2), 0.95 (t, JH−H = 7.2, 3H,
CH2CH3).
13C{1H}-APT NMR (100.4 MHz, CDCl3, 253 K): δ 172.4
(d, JC−Rh = 34.7, Rh−CNHC), 169.6 (CO), 147.1 (s, C8a), 137.7 (s,
C7), 124.7 (s, C8), 124.3 (s, C6), 121.3 (s, C4a), 121.0 and 117.8 (both
s, C12,13), 118.8 (s, C5), 71.9 (d, JC−Rh = 12.7, C4), 50.9 (d, JC−Rh = 7.7,
C3), 49.3 (s, NCH2CH2), 49.0 (s, C11), 33.6 (s, NCH2CH2), 20.5
(C9), 19.9 (s, CH2CH3), 14.3 (s, CH2CH3), 11.7 (C10).
RhCl(κ-C,η2-ICouvin)2 (8d). The complex was prepared as
described for 7a starting from [Rh(μ-OCH3)(cod)]2 (106 mg, 0.2
mmol), 2d (254 mg, 0.8 mmol), and NaOCH3 (22 mg, 0.4 mmol).
Yield: 160 mg (57%). Anal. Calcd for C34H32N4O4RhCl: C, 58.42; H,
4.61; N, 8.02. Found: C, 58.25; H, 4.49; N, 7.84. 1H NMR (300 MHz,
DMSO-d6, 298 K): δ 8.01 (dd, JH−H = 16.0, 9.0, 2H, NCH=CH2), 7.62
(d, JH−H = 8.0, 2H, H5), 7.57 and 6.98 (both d, JH−H = 2.1, 4H, H12,13),
7.08 (d, JH−H = 8.0, 2H, H6), 5.37 (dd, JH−H = 16.0, 1.6, 2H, NCH
CH2), 4.79 (dd, JH−H = 9.0, 1.6, 2H, NCHCH2), 4.02 and 3.78
(both d, JH−H = 14.1, 4H, H11), 3.64 (d, JH−Rh = 1.2, 2H, H3), 2.18 (s,
6H, H9), 1.89 (s, 6H, H10).
13C{1H}-APT NMR (75.1 MHz, DMSO-
d6, 298 K): δ 171.1 (d, JC−Rh = 35.5, Rh−CNHC), 166.7 (CO), 146.6
(s, C8a), 136.8 (s, C7), 134.1 (s, NCHCH2), 124.0 (s, C6), 123.3 (s,
C8), 120.7 (s, C5), 119.4 and 117.0 (both s, C12,13), 117.0 (s, C4a), 99.2
(s, NCHCH2), 72.9 (br, C4), 51.1 (d, JC−Rh = 6.2, C3), 48.7 (s, C11),
19.3 (C9), 10.5 (C10).
RhCl(κ-C,η2-BzICouall)2 (9). The complex was prepared as
described for 7a starting from [Rh(μ-OCH3)(cod)]2 (106 mg, 0.2
mmol), 1e (305 mg, 0.8 mmol), and NaOCH3 (22 mg, 0.4 mmol).
Yield: 120 mg (32%). Satisfactory elemental analysis could not be
obtained. HRMS (ESI) m/z Calcd for RhC40H40N4O4 (M − Cl−):
791.2099. Found: 791.210. 1H NMR (400 MHz, CDCl3, 253 K): δ
7.71 (d, JH−H = 8.2, 2H, H5), 7.63 and 5.37 (both d, JH−H = 18.4, 4H,
H11), 7.4−7.0 (10H, H6,14−17), 5.46 (s, 2H, H3), 4.33 (m, 6H,
NCH2CH), 3.01 (d, JH−H = 7.8, 2H, NCH2CHCH2), 2.64 (d,
JH−H = 11.0, 2H, NCH2CHCH2), 2.44 (s, 6H, H9), 2.41 (s, 6H,
H10).
13C{1H}-APT NMR (100.4 MHz, CDCl3, 253 K): δ 195.6 (d,
JC−Rh = 35.7, Rh−CNHC), 161.5 (CO), 152.8 (s, C4), 151.3 (s, C8a),
142.8 (s, C7), 134.7 and 133.0 (both s, C12,13), 126.6 (s, C6), 125.0 (s,
C8), 123.6 and 123.0 (both s, C15,16), 121.0 (s, C5), 115.0 (s, C4a),
110.5 and 110.4 (both s, C14,17), 109.6 (s, C3), 59.3 (d, JC−Rh = 12.7,
NCH2CH), 50.4 (s, NCH2CH), 49.2 (d, JC−Rh = 5.6,
NCH2CHCH2), 47.2 (s, C11), 20.7 (C9), 11.8 (C10).
Crystal Structure Determination. Single crystals for the X-ray
diffraction studies were grown by slow evaporation of CDCl3 (3c, 4a,
and 8b) or CH2Cl2 (7b and 9) solutions. X-ray diffraction data were
collected at 100(2) K on a Bruker APEX SMART CCD diffractometer
with graphite-monochromated Mo−Kα radiation (λ = 0.71073 Å)
using narrow ω rotations(0.3−0.6°). Intensities were integrated and
corrected for absorption effects with SAINT+37 and SADABS38
programs, both included in APEX2 package. The structures were
solved by the Patterson method with SHELXS-9739 and refined by full
matrix least-squares on F2 with SHELXL-2014,40 under WinGX.41
Crystal Data for 3c. C35H36ClN2O2Rh·CHCl3; M = 774.38 g·
mol−1; triclinic, P1 ̅; a = 12.3496(7) Å, b = 12.3541(7) Å, c =
13.3569(8) Å, α = 106.6520(10)°, β = 109.7080(10)°, γ =
107.9120(10)°, V = 1643.12(17) Å3; Z = 2; Dc = 1.565 g Cm
−3; μ
= 0.882 mm−1; F(000) = 792; yellow prism, 0.300 × 0.150 × 0.130
mm; ϑmin = 1.799°, ϑmax = 28.553°; limiting indexes −15 ≤ h ≤ 16,
−16 ≤ k ≤ 15, −17 ≤ l ≤ 17; reflections collected/unique 19 234/
7636 (Rint = 0.0236); data/restraints/parameters 7636/0/409; GOF
1.059; R1 = 0.0303 [I > 2σ(I)], 0.0367 (all data); wR
2 = 0. 0733 [I >
2σ(I)], 0. 0779 (all data); largest diff. peak/hole 0.554 and −0.402 e·Å
−3. CCDC deposit number: 1569679.
Crystal Data for 4a. C30H32ClN2O2Rh·2CHCl3; M = 829.67 g·
mol−1; triclinic, P1 ̅; a = 11.3385(6) Å, b = 11.9379(6) Å, c =
14.9149(11) Å, α = 98.3830(10)°, β = 105.5410(10)°, γ =
115.1550(10)°, V = 1680.71(18) Å3, Z = 2; Dc = 1.639 g Cm
−3; μ
= 1.098 mm−1; F(000) = 840; yellow prism, 0.220 × 0.200 × 0.120
mm; ϑmin = 1.974°, ϑmax = 27.103°; limiting indexes −14 ≤ h ≤ 14, −
15 ≤ k ≤ 15, − 19 ≤ l ≤ 19; reflections collected/unique 27 191/7387
(Rint = 0.0245); data/restraints/parameters 7387/0/399; GOF 1.028;
R1 = 0.0276 [I > 2σ(I)], 0.0310(all data); wR
2 = 0.0659 [I > 2σ(I)],
0.0683 (all data); largest diff. peak/hole 1.259/−0.718 e·Å−3. CCDC
deposit number: 1569680.
Crystal Data for 7b. C46H48ClN4O4Rh·CH2Cl2; M = 944.17 g·
mol−1; monoclinic, P21/n; a = 12.5553(9) Å, b = 12.9395(9) Å, c =
26.0875(18) Å, β = 99.0930(10)°, V = 4184.9(5) Å3; Z = 4; Dc =
1.499 g Cm−3; μ = 0.650 mm−1; F(000) = 1952; yellow prism, 0.210 ×
0.160 × 0.050 mm; ϑmin = 2.231°, ϑmax = 28.674°; limiting indexes
−16 ≤ h ≤ 16, − 15 ≤ k ≤ 16, − 35 ≤ l ≤ 34; reflections collected/
unique 35 830/9975 (Rint = 0.0614); data/restraints/parameters 9975/
0/538; GOF 1.146; R1 = 0.0521 [I > 2σ(I)], 0.0773 (all data); wR
2 =
0.0845 [I > 2σ(I)], 0.0920 (all data); largest diff. peak/hole 0.762/−
0.715 e·Å−3. CCDC deposit number: 1569681.
Crystal Data for 8b. C38H44ClN4O4Rh·4CHCl3; M = 1236.60 g·
mol−1; monoclinic, C2/c; a = 19.6171(11) Å, b = 17.6333(11) Å, c =
15.1016(9) Å, β = 98.1160(10)°, V = 5171.5(5) Å3; Z = 4; Dc = 1.588
g Cm−3; μ = 1.046 mm−1; F(000) = 2504; yellow prism, 0.250 × 0.175
× 0.150 mm; ϑmin = 2.097°, ϑmax = 28.620°; limiting indexes −25 ≤ h
≤ 25, − 23 ≤ k ≤ 23, − 19 ≤ l ≤ 19; reflections collected/unique
29 801/6241 (Rint = 0.0338); data/restraints/parameters 6241/30/
328; GOF 1.026; R1 = 0.0318 [I > 2σ(I)], 0.0410 (all data); wR
2 =
0.0658 [I > 2σ(I)], 0.0706 (all data); largest diff. peak/hole 1.031/−
0.650 e·Å−3. CCDC deposit number: 1569682.
Crystal Data for 9. C44H40ClN4O4Rh·3CH2Cl2; M = 1081.94 g·
mol−1; triclinic, P1̅; a = 12.5925(9) Å, b = 13.9807(10) Å, c =
15.0183(18) Å, α = 102.9200(10)°, β = 93.5190(10)°, γ =
115.0090(10)°, V = 2298.8(4) Å3; Z = 2; Dc = 1.563 g Cm
−3; μ =
0.828 mm−1; F(000) = 1104; colorless prism, 0.250 × 0.120 × 0.070
mm; ϑmin = 1.413°; ϑmax = 26.370°; limiting indexes −15 ≤ h ≤ 15, −
17 ≤ k ≤ 17, − 18 ≤ l ≤ 18; reflections collected/unique 24 768/9342
(Rint = 0.0364); data/restraints/parameters 9342/0/596; GOF 1.052;
R1 = 0. 0437 [I > 2σ(I)], 0. 0585 (all data); wR
2 = 0. 0991 [I > 2σ(I)],
0. 1065 (all data); largest diff. peak/hole 0.575 /−0. 896 e·Å−3. CCDC
deposit number: 1569683.
Computational Details. All DFT theoretical calculations have
been carried out using the Gaussian program package.42 The B3LYP
method43 has been employed, for both energies and gradient
calculations, and the “ultrafine” grid has been used in all cases. The
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def2-SVP basis set44 has been selected for all atoms. The nature of the
stationary points has been confirmed by analytical frequency analysis.
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Chem., Int. Ed. 2017, 56, 865. (h) Azpíroz, R.; Sharma, P.; Peŕez-
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Dixneuf, P. H.; Oro, L. A. Organometallics 2011, 30, 5208. (b) Palacios,
L.; Di Giuseppe, A.; Opalinska, A.; Castarlenas, R.; Peŕez-Torrente, J.
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